1,049 results on '"Shpilberg, Ofer"'
Search Results
2. Novel pyrrolidine-aminophenyl-1,4-naphthoquinones: structure-related mechanisms of leukemia cell death
3. Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms
4. Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy
5. MicroRNA-15a-5p acts as a tumor suppressor in histiocytosis by mediating CXCL10-ERK-LIN28a-let-7 axis
6. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
7. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing
8. Supplementary Table S2 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
9. Data from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
10. Supplementary Figure S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
11. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.
12. Rituximab maintenance improves overall survival of patients with follicular lymphoma—Individual patient data meta-analysis
13. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
14. Supplementary Table 2 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab
15. Supplementary Figure 3 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab
16. Supplementary Figure 1 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab
17. Supplementary Table 1 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab
18. Supplementary Figure 2 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab
19. Supplementary Table 3 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab
20. Supplementary Table 4 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab
21. Supplementary Methods from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab
22. Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
23. AL amyloidosis clonal plasma cells are regulated by microRNAs and dependent on anti‐apoptotic BCL2 family members
24. Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study
25. Mutant PIK3CAis a targetable driver alteration in histiocytic neoplasms
26. Restoration of miR-424 suppresses BCR–ABL activity and sensitizes CML cells to imatinib treatment
27. MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR–ABL protein
28. Non-Coding RNAs Regulate Novel Signaling Pathways in AL Amyloidosis That Are Targetable By BCL2, PI3K and MEK Inhibitors
29. Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.
30. Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network
31. Inhibition of MAPK-ERK Signaling Pathway Overcomes Microrna-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma
32. First line and salvage therapy with total therapy 3-based treatment for multiple myeloma––An extended single center experience
33. The Role of Hematopoietic Growth Factors in Aplastic Anemia: An Evidence-Based Perspective
34. Erratum to: The Role of Hematopoietic Growth Factors in Aplastic Anemia: An Evidence-Based Perspective
35. Novel pyrrolidine-aminophenyl-1,4-naphthoquinones: structure-related mechanisms of leukemia cell death
36. Tailoring the GVHD prophylaxis regimen according to transplantation associated toxicities—Substituting the 3rd dose of methotrexate to mycophenolate mofetil
37. Mycophenolate mofetil vs. methotrexate for the prevention of graft-versus-host-disease – Systematic review and meta-analysis
38. Gold nanoparticles stabilize peptide-drug-conjugates for sustained targeted drug delivery to cancer cells
39. Enhanced adhesion/migration and induction of Pyk2 expression in K562 cells following imatinib exposure
40. The role of 18F-FDG PET/CT for the diagnosis of infections in patients with hematological malignancies and persistent febrile neutropenia
41. Retinoic acid induces adhesion and migration in NB4 cells through Pyk2 signaling
42. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth
43. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients
44. Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia
45. Second-generation tyrosine kinase inhibitors reduce telomerase activity in K562 cells
46. Characteristics of initial compared with subsequent bacterial infections among hospitalised haemato-oncological patients
47. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
48. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial
49. MicroRNA-15a-5p acts as a tumor suppressor in histiocytosis by mediating CXCL10-ERK-LIN28a-let-7 axis
50. The Role of Non-Coding RNAs in the Pathogenesis of AL Amyloidosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.